公开(公告)号：US20250027949A1

公开(公告)日：2025-01-23

申请号：US18906699

申请日：2024-10-04

Applicant: AJINOMOTO CO., INC.

Inventor： Koichi AZUMA ,  Kenta MUROTANI ,  Tetsuro SASADA ,  Tomoyuki TAGAMI ,  Asami HAGIWARA ,  Akira IMAIZUMI ,  Sachise KARAKAWA ,  Mika KAWASAKI ,  Yohei MIYAGI ,  Tomohiko TAMURA ,  Haruhiro SAITO ,  Yoshiro NAKAHARA ,  Feifei WEI ,  Rika KASAJIMA ,  Huihui XIANG ,  Tatsuma BAN

IPC: G01N33/68

Abstract: An evaluating method includes an evaluating step of evaluating a relative pharmacological action of a combination of an immune checkpoint inhibitor and an anticancer drug as a combination drug compared with a pharmacological action of an immune checkpoint inhibitor alone in a subject to be evaluated, using (i) a concentration value of at least one metabolite among Glu, Arg, Orn, Cit, His, Val, Phe, Tyr, Met, Pro, Asn, Leu, Lys, Thr, Ile, Gln, Ala, Ser, a-ABA, Trp, Gly, AnthA, hKyn, hTrp, Kyn, KynA, NP, QA, and XA in blood of the subject to be evaluated, or (ii) a value of a formula in the absence of use of an anticancer drug as a combination drug and a value of the formula in the presence of the use that are calculated using the concentration value and the formula including an explanatory variable to be substituted with the concentration value and an explanatory variable on the presence or absence of the use.

公开(公告)号：US20220268790A1

公开(公告)日：2022-08-25

申请号：US17730484

申请日：2022-04-27

Applicant: AJINOMOTO CO., INC.

Inventor： Sachise KARAKAWA ,  Tomoyuki TAGAMI ,  Rumi NISHIMOTO ,  Shinya KIKUCHI ,  Akira IMAIZUMI ,  Koichi AZUMA ,  Tomoaki HOSHINO ,  Takaaki TOKITO ,  Hidenobu ISHII ,  Norikazu MATSUO

IPC: G01N33/94 ,  G01N33/68 ,  G16H10/40 ,  G16H50/30

Abstract: An evaluating method includes an evaluating step of evaluating a pharmacological action of an immune checkpoint inhibitor in a subject to be evaluated, using (i) a concentration value of at least one metabolite among Glu, Arg, Orn, Cit, His, Val, Phe, Tyr, Met, Pro, Asn, Leu, Lys, Thr, Ile, Gln, Ala, Ser, a-ABA, Trp, Gly, AnthA, hAnthA, hIAA, hKyn, hTrp, IAA, ILA, Kyn, KynA, NFKyn, NP, PA, QA, Serot, and XA in blood of the subject to be evaluated, or (ii) a value of a formula calculated using the concentration value and the formula including an explanatory variable to be substituted with the concentration value.